ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner
Zoetermeer, Netherlands - 13 January 2026 - Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
ORTEC, a global leader in supply chain planning and workforce management software, today announced the strategic acquisition of Klages & Partner, a German developer of clinical staff management software for hospitals, clinics, and care facilities meeting the complex demands of modern healthcare. Klages & Partner serves over 200 healthcare customers, primarily in Germany.
This acquisition supports ORTEC’s Workforce Management strategic objective to strengthen its position in the German healthcare sector, building on decades of experience and established leadership in workforce scheduling for the Dutch healthcare market, as well as an existing customer base across Belgium, Finland, Germany, the United Kingdom, and Australia. It expands ORTEC’s German industry-specific expertise while maintaining focus on delivering clarity, reliability, and human-centric technology across its solutions portfolio.
“Klages & Partner shares our commitment, quite simply, to making work work better for people in complex operational environments,” said Georgios Sarigiannidis, CEO of ORTEC. “Together, we can offer healthcare organizations even more powerful, user-friendly tools to plan, manage, and optimize their workforce, ultimately improving care delivery and staff satisfaction.”
Founded in 1991, Klages & Partner develops and distributes software designed hand-in-hand with healthcare professionals to address the unique challenges of clinical staff planning. Their solutions simplify complex workforce scheduling while ensuring fairness, efficiency, and compliance, enabling hospital and care facility teams to focus on the work that matters most: patient care.
ORTEC and Klages & Partner have a shared commitment to customer value, practical innovation, and building solutions that genuinely support healthcare professionals. ORTEC brings long-standing experience in workforce scheduling for healthcare organizations, while Klages & Partner contributes deep local market knowledge and trusted relationships within the German care sector.
The transaction closed at the end of December 2025.
About Klages & Partner
Klages & Partner develops and distributes clinical staff management software in close collaboration with hospital professionals. Serving more than 200 customers, primarily in Germany, the company’s mission is to make workforce planning in healthcare effective, fair, and sustainable.
Contacts
Rebecca NobleVice President Corporate CommunicationsORTEC BV
Media Contact
Images
About ORTEC
For more than 40 years ORTEC builds software for planning supply chains and managing workforces. We help organizations figure out the best way to use their people and resources, even when things change. Using our trusted, AI-powered technology dissolves noise and friction so people can stay in the flow. Our goal is simple: let our software provide confidence, fairness, and reliability, so everyone can focus on the work that truly matters. ORTEC is backed by Battery Ventures. Discover more at ortec.com.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 12:34:15 CET | Press Release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ESSL leading study to find where and why damaging hail is getting worse12.1.2026 13:38:03 CET | Press Release
Wiener Neustadt, Austria jan 12, 2026 - First comprehensive global study of very large hail in a changing climate reveals contrasting trends and different causes.
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 13:27:37 CET | Press Release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:20:00 CET | Press Release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing. The anniversary edition underlines how natural remedies, therapeutic landscapes and evidence-based spa medicine represent a distinctive European strength with growing relevance for public health systems. Across Europe, medical spas are increasingly recognised as complementary health infrastructures supporting prevention, rehabilitation and long-term quality of life. “Medical spas today are strategic health infrastructures supporting prevention, rehabilitation and long-term wellbeing,” says Dr Siyka Katsarova, President of ESPA and Advisor to the EU’s New Lifestyle Strategy. The publication showcases Europe’s exceptional therapeutic diversity — ranging from thermal and mineral waters, climate therapy and thalassotherapy t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom